Rifabutin Is Active against Mycobacterium abscessus in Mice

There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin...

Descripción completa

Detalles Bibliográficos
Autores principales: Dick, Thomas, Shin, Sung Jae, Koh, Won-Jung, Dartois, Véronique, Gengenbacher, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985736/
https://www.ncbi.nlm.nih.gov/pubmed/31767722
http://dx.doi.org/10.1128/AAC.01943-19
Descripción
Sumario:There is no reliable cure for Mycobacterium abscessus lung disease. Rifampin is not used clinically due to poor in vitro potency. In contrast, we have shown that rifabutin, another approved rifamycin used to treat tuberculosis, is potent in vitro against M. abscessus. Here, we report that rifabutin is as active as clarithromycin against M. abscessus K21 in NOD.CB17-Prkdc(scid)/NCrCrl mice. This suggests that rifabutin should be considered a repurposing candidate for patients with M. abscessus disease.

Ejemplares similares